• A Simple Swab Could Change How Doctors Detect Endometrial Cancer

    Jun 16 | Clinical Research News | For the roughly 1.3 to 2 million women who visit their doctor each year with abnormal postmenopausal bleeding, the diagnostic journey has long been an uncomfortable one. The standard workup typically involves an endometrial biopsy—an invasive, often painful procedure that, despite its widespread use, fails to yield a conclusive diagnosis in more than 30% of cases. Two veteran diagnostics executives think there's a better way, and they're betting nearly $45 million in venture funding on it. More

  • Urine Liquid Biopsy Shows Strong Promise for Guiding Bladder Cancer Treatment — Clinical Trials on the Horizon

    Jun 11 | Clinical Research News | A novel urine-based liquid biopsy developed at Stanford University is showing remarkable accuracy in predicting bladder cancer recurrence and may soon reshape how clinical trials enroll and treat patients. The test, developed by urologic oncologist Joseph Liao, M.D., and colleagues, filters out age-related background mutations in urine to produce a cleaner, more reliable signal for detecting residual cancer after surgery and immunotherapy. More

  • The Scope of Things: Measuring Equity in Cancer Care

    Jun 09 | Clinical Research News | In the latest episode of The Scope of Things, Eugene Manley, Jr., founder and CEO of the STEMM & Cancer Health Equity Foundation, explains how underrepresented populations, including Black, Hispanic, Indigenous, rural, low-income, immigrant, underinsured, and uninsured communities, are less likely to receive guideline-aligned biomarker testing and less likely to be asked about clinical trial participation at all. More

  • Regulatory Outlook in Diagnostics Innovative and Uncertain

    Jun 04 | Clinical Research News | The diagnostics industry is at the intersection of enormous clinical development and technological change, enabling first-ever detection milestones heavily driven by artificial intelligence and multi-biomarker tests. But it has increasingly been coming into conflict with a decades-old regulatory system that didn’t anticipate these technological changes and a political environment that favors U.S. competition and innovation but is also interested in cutting the budget. More

  • A ‘Credit-Score-Like’ Risk Assessment System for Investigative Drugs

    Jun 03 | Clinical Research News | VeriSIM Life is building the “full-stack predictive infrastructure” to help pharma companies foresee the challenges ahead in translating a molecule from laboratory discovery to a successful human therapy. The help comes in the form of a dynamic, “credit-score-like” assessment of the risk with inherent explainability and trust. More

  • Phesi Highlights Disconnect Between Protocols and Outcomes, Warns of AI Repetition

    Jun 02 | Clinical Research News | An analysis released by Phesi suggests that the systematic use of historical protocol templates without using patient data and context to guide protocol design leads to flaws being scaled, rather than solved, by AI. More

  • Flatiron’s AI-Powered Platform, Verana Health Ovarian Cancer Database, Eir Partners Invests in QuartzBio

    May 29 | Clinical Research News | uMotif launches its new Scientific Consulting Services; Veeva Systems announces Veeva Falcon; b.well Connected Health and myTomorrows announce a partnership; and more. More

  • Insider Views on the FDA’s Evolving Relationship with AI

    May 27 | Clinical Research News | The Food and Drug Administration is undergoing a major step change in how it regulates and evaluates drugs, marked by a shift toward real-time clinical trials, an agency-wide rollout of generative AI tools to speed up drug application reviews, and a radical transparency push that includes public disclosure of complete response letters sent to pharmaceutical companies explaining why a drug application was rejected. More

  • Follow the Money: AI Drug Design Engine Development, Multiple Myeloma Trials, More

    May 26 | Clinical Research News | Isomorphic Labs continues to develop its AI drug design engine; CellCentric advances in multiple myeloma; and more. More
View more articles
 
DXX-Industry-spotlight
SOT

The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News Senior writer Deborah Borfitz welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider’s look at clinical research today.

Read More